Clinical characteristics of Chinese pan-cancer patients
Consisted of 1504 advanced pan-cancer patients and 134 early-stage NSCLC
patients (Fig.1), this study included 1638 Chinese pan-cancer patients
who had undergone tumor profiling with a 1021-gene panel and the
prevalence of HLA-I LOH was analyzed. To assess the consistency of HLA-I
LOH analysis between 1021-gene panel sequencing and WES, 45 samples were
processed with both approaches, resulting in a consistency of 95.6%
(43/45) (Fig.2A) which suggested that the 1021-gene panel sequencing is
capable of detecting HLA-I genotype and HLA-I LOH status in this cohort.
Among the 1638 patients, 24 (22 advanced patients and 2 early-stage
patients) were excluded due to homozygosity at all three HLA-I loci
(HLA-A, HLA-B, HLA-C), remaining with 1482 advanced pan-cancer patients
and 132 early-stage NSCLC patients (Fig.1) for further analysis. The
clinical characteristics of the study cohort are listed in Table 1. As
shown in Table 1, patients in the HLA-I LOH group had a higher diagnosis
age than those in the HLA-I stable group (median age 59 vs. 57,
p=0.011), while no significant difference was found in gender (p=0.204).
The distribution of patients among different cancer types and clinical
data are shown in Supplementary Table 1.